Rush B D, Wilkinson K F, Nichols N M, Ochoa R, Brunden M N, Ruwart M J
Diabetes and GI Diseases, Upjohn Company, Kalamazoo, Michigan 49001.
Prostaglandins. 1989 Jun;37(6):683-93. doi: 10.1016/0090-6980(89)90105-6.
Studies were conducted to assess the possible protective action of 16,16-dimethyl prostaglandin E2 (DMPG) against acute aflatoxin B1 (AFB1) induced hepatic injury in the rat. Evaluation of liver damage by histopathologic techniques and clinical chemistry indicated that hepatic necrosis was ameliorated by treatment with DMPG even though binding of radiolabeled (3H)-AFB1 to hepatic DNA was unaffected by this prostaglandin. However, DMPG did not protect rats against AFB1-induced mortality. These data suggest that hepatic protection by DMPG was due to mechanisms other than an interference with the activation or hepatic binding of AFB1.
开展了多项研究,以评估16,16 - 二甲基前列腺素E2(DMPG)对大鼠急性黄曲霉毒素B1(AFB1)诱导的肝损伤可能具有的保护作用。通过组织病理学技术和临床化学对肝损伤进行评估,结果表明,尽管放射性标记的(3H)-AFB1与肝DNA的结合不受这种前列腺素的影响,但用DMPG治疗可减轻肝坏死。然而,DMPG并不能保护大鼠免受AFB1诱导的死亡。这些数据表明,DMPG对肝脏的保护作用是由干扰AFB1的活化或肝脏结合以外的机制所致。